Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell and is considered one of the most essential molecules in cellular biochemistry. First identified in 1906 by British biochemists Arthur Harden and William Young, NAD+ has since become a central focus of research into energy metabolism, DNA repair, and the biology of aging. Although NAD+ is technically a dinucleotide rather than a peptide, it is frequently grouped within peptide and molecular research discussions due to its prominent role in longevity science and its interaction with numerous protein-based signaling pathways.
Investigators study NAD+ because cellular levels of this coenzyme have been observed to decline with age, a phenomenon that researchers hypothesize may contribute to mitochondrial dysfunction and age-related metabolic changes. This article reviews the current state of NAD+ research, its proposed mechanisms of action, and areas of active scientific inquiry.
NAD+ functions primarily as a redox cofactor, shuttling electrons between molecules during cellular respiration. In its oxidized form (NAD+), it accepts electrons to become NADH, which then donates those electrons to the mitochondrial electron transport chain to support ATP production. This cycling is fundamental to how cells generate usable energy from nutrients.
Beyond its role in energy metabolism, NAD+ serves as a required substrate for several families of signaling enzymes. Research has identified three major NAD+-consuming enzyme classes: sirtuins, a family of deacetylases linked to gene expression and stress resistance; PARPs (poly-ADP-ribose polymerases), which are involved in DNA damage repair; and CD38, an ectoenzyme implicated in immune signaling and calcium regulation. Studies indicate that each of these enzymes cleaves NAD+ during its catalytic activity, meaning cellular demand can deplete NAD+ pools over time.
Researchers have also characterized several biosynthetic pathways through which cells generate NAD+, including the de novo pathway from tryptophan, the Preiss-Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide. The salvage pathway is considered the dominant route in mammalian cells.
A substantial body of preclinical research has examined how NAD+ availability influences mitochondrial health. Studies in rodent models suggest that restoring NAD+ levels through precursor supplementation may support mitochondrial biogenesis and improve markers of oxidative metabolism. Investigators have observed that age-related declines in NAD+ correlate with reduced mitochondrial efficiency in multiple tissue types.
NAD+ has become a focal point in geroscience research. Work led by laboratories including those of David Sinclair at Harvard Medical School has explored connections between NAD+ levels, sirtuin activity, and biological aging markers. Preclinical data suggests that boosting NAD+ in aged mice may influence measures such as insulin sensitivity, physical endurance, and certain epigenetic markers, though researchers emphasize these findings have not been consistently replicated in human trials.
Because PARP enzymes consume NAD+ during DNA repair, researchers have investigated whether chronic DNA damage accelerates NAD+ depletion. Studies indicate that cells experiencing high genotoxic stress exhibit reduced NAD+ availability, which may in turn limit sirtuin-mediated protective functions. This interplay has been proposed as a mechanistic link between DNA damage accumulation and age-related cellular decline.
Preclinical investigations have explored NAD+ in models of neurodegeneration. Animal studies have examined whether NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) may support neuronal resilience under oxidative stress conditions. Researchers have noted changes in markers associated with cognitive performance in rodent models, though translation to human neurological conditions remains under active investigation.
Most foundational NAD+ research has been conducted in cell culture and animal models. Rodent studies have reported that administration of NAD+ precursors may restore tissue NAD+ concentrations, improve metabolic parameters, and extend measures of healthspan in certain strains. However, investigators consistently caution that findings in mice do not automatically translate to humans.
Early-phase human clinical trials have primarily focused on NAD+ precursors rather than NAD+ itself, since direct NAD+ supplementation faces bioavailability challenges. Published trials of NR and NMN have reported that these compounds can raise blood NAD+ metabolite levels in human participants. Researchers have observed modest changes in some metabolic biomarkers, though larger and longer trials are needed to establish whether these shifts correspond to meaningful physiological outcomes.
In published clinical investigations of NAD+ precursors, tolerability has generally been reported as favorable at the doses studied. Commonly noted observations in trial participants have included mild gastrointestinal effects and transient flushing with certain precursor forms. Long-term safety data in humans remains limited, and researchers emphasize that extended-duration studies are necessary before drawing firm conclusions about chronic use. As with any investigational compound, safety findings are context-specific and should not be interpreted as guarantees.
NAD+ occupies a central position in cellular biology, linking energy metabolism, DNA repair, and signaling pathways implicated in aging. Current research suggests that NAD+ levels decline with age and that this decline may contribute to several hallmarks of cellular aging. While preclinical studies have produced encouraging findings regarding NAD+ precursor supplementation, robust human clinical evidence remains in relatively early stages. Continued investigation, particularly larger randomized human trials, will be essential to clarify the translational relevance of NAD+ biology for healthspan and metabolic research.
I understand these products are for research use only and not for use in people or pets. I am purchasing these items for laboratory or research purposes only. They are not for human or animal use, not medicine, and not for diagnosing, treating, or curing any condition. I will follow all applicable laws and safe handling rules. I accept that this website, and our affiliates, are not responsible for how I use or store these items once delivered, to the fullest extent allowed by law. In accordance with industry guidelines, access to this website is restricted to individuals 21 years of age or older. This site provides information and products strictly for laboratory and research use. Are you over 21 years of age?
